Comparative Pharmacology
Head-to-head clinical analysis: GLYCORT versus TOLTERODINE TARTRATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GLYCORT versus TOLTERODINE TARTRATE.
GLYCORT vs TOLTERODINE TARTRATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucocorticoid receptor agonist; modulates gene expression to produce anti-inflammatory and immunosuppressive effects.
Competitive antagonist of muscarinic acetylcholine receptors (M1, M2, M3, M4, M5) with relative selectivity for the bladder over salivary glands. Reduces detrusor muscle contractility and bladder pressure.
Intravenous: 2 mg/kg every 12 hours; Oral: 20 mg twice daily.
2 mg orally twice daily. May be reduced to 1 mg orally twice daily based on tolerability.
None Documented
None Documented
3.5 hours (terminal); prolonged in hepatic impairment (up to 8 hours) and severe renal impairment (up to 6 hours)
Terminal elimination half-life is 2-3 hours in extensive metabolizers (CYP2D6) and approximately 9 hours in poor metabolizers. In clinical context, dosing interval is adjusted in poor metabolizers (e.g., 2 mg twice daily reduced to 2 mg once daily).
Renal: 70% as unchanged drug; biliary/fecal: 25% (metabolites); 5% other
Renal (77%) and fecal (17%): approximately 14% as unchanged tolterodine, 51% as the active 5-hydroxymethyl metabolite, and 12% as other metabolites. Biliary excretion contributes minimally.
Category C
Category A/B
Anticholinergic
Anticholinergic